drugset / Trial / NCT04993677
A Study of SEA-CD40 Given With Other Drugs in Cancers
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This trial is being done to see if an experimental drug (SEA-CD40) works when it's given with other cancer drugs to treat some types of cancer. It will also study side effects from the drug. There are 2 parts in this trial. In one part, participants have melanoma that has come back after treatment or can't be removed by surgery. Participants in this part will get SEA-CD40 and pembrolizumab. In the other part, participants have non-small cell lung cancer (NSCLC) that has spread through their body. These participants will get SEA-CD40, pembrolizumab, carboplatin, and pemetrexed.
Timeline
- Start
- 2021-10-06
- Primary completion
- 2024-01-03
- Completion
- 2024-11-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CIFURTILIMAB | Monoclonal antibody | — | Intravenous |
| Background | Carboplatin | Small molecule | — | Intravenous |
| Background | Pembrolizumab | Monoclonal antibody | — | Intravenous |
| Background | Pemetrexed | Small molecule | — | Intravenous |